FOR PREVIEW ONLY (Print)

Andrew E. Hendifar, MD

Medical Director, Pancreatic Cancer

Assistant Professor, Medicine

Cedars-Sinai Medical Center
8700 Beverly Blvd.
AC 1042C
Los Angeles, CA 90048

Phone:

310-423-2217

Fax:

310-967-8486

Parking Instructions:

Parking is available in Lot 6.

Andrew E. Hendifar, MD

Medical Director, Pancreatic Cancer

Assistant Professor, Medicine

  • IM/Hematology/Oncology
  • Gastrointestinal Oncology

Carcinoid Tumors

Colorectal Cancer (Colon, Rectal)

Pancreatic Cancers

Andrew Hendifar, MD, is the medical oncology lead for the Gastrointestinal Disease Research Group at Cedars-Sinai and co-director of Pancreas Oncology. He and his colleagues from Surgery, Gastroenterology, Radiation Oncology and Radiology have formed multidisciplinary teams that specialize in the treatments of pancreatic cancer, and carcinoid and neuroendocrine tumors. His current research efforts are focused on developing new therapies for pancreatic cancer and neuroendocrine tumors. Hendifar is the primary investigator for several groundbreaking therapies, including radioimmunotherapy for neuroendocrine and pancreatic cancer. He is helping to develop the use of stromal agents and gene-targeted therapies in the treatment of pancreatic cancer and neuroendocrine tumors. Hendifar's research involves studying cachexia in his cancer patients. He has developed a treatment protocol in pancreatic cancer cachexia that will increase understanding of this phenomenon. The goal is to develop new therapies for this condition. One treatment, an anti-inflammatory agent, is already being investigated in colon cancer patients. Hendifar is also the primary investigator for several trials in the treatment of pancreatic cancer, colon cancer, and neuroendocrine tumors. Through partnerships with SWOG (formerly the Southwest Oncology Group), the Pancreas Cancer Research Team and the Pancreatic Cancer Action Network, Cedars-Sinai patients have access to the best investigational treatments available. Hendifar's work has been published in prestigious journals, including the Lancet, Cancer, Journal of Clinical Oncology and Clinical Cancer Research. Hendifar has displayed deep subject-matter knowledge in presentations for organizations such as the National Institutes of Health and the American Society of Clinical Oncology. His patient care has also been recognized, as he has been named a "Top Doctor" and a "Super Doctor."

View NIH Biographical Sketch as a PDF

  • Medical School: Tulane University School of Medicine, 2003
  • Internship: Los Angeles County + USC Medical Center, 2006
  • Residency: Los Angeles County + USC Medical Center, 2007
  • Fellowship: University of Southern California, 2010

View CV as a PDF

  • Course Director: LACNETS & CFCF Annual Neuroendocrine Tumor Patient & Caregiver Educational Conference, 2015-present
  • Super Doctors, 2013-present
  • 12th Annual Meeting, Randomized Phase II Study of BEZ235 or Everolimus (EVE) in Patients with Advanced Pancreatic Neuroendocrine Tumors (pNET), European Neuroendocrine Tumor Society, 2015
  • 20th annual BRCA Gene Symposium, A Study of Rucaparib in Patients with Pancreatic Cancer and a Known Deleterious BRCA Mutation, 2014
  • Top Doctors, 2010
  • Brautbauer Teaching Award, 2007
  • First Prize, American College of Physicians Abstract, 2005
  • American Society of Clinical Oncology, 2003
  • American Federation for Medical Research Student Recognition Award, 2003

Show moreShow less

Click here for a list of peer-reviewed publications.

  • Iriana S, Ahmed S, Gong J, Annamalai AA, Tuli R, et al. Targeting mTOR in Pancreatic Ductal Adenocarcinoma. Front Oncol. 2016;6:99.
  • Osipov A, Naziri J, Hendifar A, Dhall D, Rutgers JK, Chopra S, Li Q, Tighiouart M, Annamalai A, Nissen NN, Tuli R. Impact of margin status and lymphadenectomy on clinical outcomes in resected pancreatic adenocarcinoma: implications for adjuvant radiotherapy. J Gastrointest Oncol. 2016 Apr;7(2):239-47.
  • Hendifar A, Osipov A, Khanuja J, Nissen N, Naziri J, Yang W, Li Q, Tuli R. Influence of Body Mass Index and Albumin on Perioperative Morbidity and Clinical Outcomes in Resected Pancreatic Adenocarcinoma. PLoS One. 2016 Mar 25;11(3):e0152172.
  • Khanuja J, Gresham G, Osipov A, Tuli R, Hendifar A. Treatment and underlying mechanisms of pancreatic cancer cachexia (PANCAX study). J Clin Oncol. 2015;33.
  • Hendifar AE, Liu S, Wolin E. The role of mTOR inhibitors in neuroendocrine tumors. mTOR Inhibition for Cancer Therapy Past, Present and Future. 2014.

Show moreShow less

English / Spanish

Make an Appointment

Call

1-800-CEDARS-1

(1-800-233-2771)

Available 24 Hours A Day

or

Many of the physicians who have medical staff privileges to practice medicine at Cedars-Sinai Medical Center are independent physicians, and not employees or agents of the hospital. These independent physicians bill separately for their services. You should contact your physician to determine their status and billing practices.

Send Email to Andrew E. Hendifar, MD